The short version
CJC-1295 and Ipamorelin are the most researched growth hormone peptide pairing in the field. They work through two separate but complementary mechanisms — one builds the GH release signal, the other triggers the release — producing a more robust and sustained GH pulse than either does alone. The mechanism is well understood, the individual compounds have meaningful human data, and their pairing is backed by a coherent biological rationale. They are not approved medicines, and they are prohibited in tested sport, but for growth hormone research they represent the most intelligently designed peptide combination available.
How they work — in plain English
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to tell your pituitary gland to produce GH. It binds the same receptor as natural GHRH but is engineered to last much longer — from minutes to several days — by attaching to albumin in the blood via Drug Affinity Complex (DAC) technology. Think of it as a sustained "press the GH accelerator" signal.
Ipamorelin works differently. It is a ghrelin receptor agonist — it mimics a separate hunger-related signal that independently tells the pituitary to release GH. It is selective for GH release without significantly raising cortisol or prolactin, which is a key advantage over older GH secretagogues. Think of it as "releasing the GH brake" through a completely different pathway.
Together, they hit two independent receptors that both drive GH output. Research suggests the combination produces GH pulses greater than the sum of the individual effects.
What the research actually shows
CJC-1295 has been studied in humans — early phase trials demonstrated sustained IGF-1 elevation lasting days after single dosing, consistent with the albumin-binding extended half-life. Ipamorelin's selectivity for the GH axis without adrenal stimulation has been demonstrated in animal models. Large-scale human trials on the combination as a paired protocol have not been published, which means the evidence for specific outcomes (body composition, recovery, anti-aging) in people is extrapolated from mechanism rather than confirmed in controlled trials.